34 related articles for article (PubMed ID: 9839589)
1. Autoantibodies against p53 are not increased in human ascites and pleural effusions.
Munker R; Stötzer O; Darsow M; Classen S; Lebeau A; Wilmanns W
Cancer Immunol Immunother; 1996 Mar; 42(3):200-1. PubMed ID: 8640849
[TBL] [Abstract][Full Text] [Related]
2. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.
Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY
Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening.
Pedersen JW; Gentry-Maharaj A; Nøstdal A; Fourkala EO; Dawnay A; Burnell M; Zaikin A; Burchell J; Papadimitriou JT; Clausen H; Jacobs I; Menon U; Wandall HH
Int J Cancer; 2014 May; 134(9):2180-88. PubMed ID: 24122770
[TBL] [Abstract][Full Text] [Related]
4. Antibody profiling with protein antigen microarrays in early stage cancer.
Liu BC; Dijohnson DA; O'Rourke DJ
Expert Opin Med Diagn; 2012 May; 6(3):187-96. PubMed ID: 23480685
[TBL] [Abstract][Full Text] [Related]
5. p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.
Creaney J; McLaren BM; Stevenson S; Musk AW; de Klerk N; Robinson BW; Lake RA
Br J Cancer; 2001 Jan; 84(1):52-6. PubMed ID: 11139313
[TBL] [Abstract][Full Text] [Related]
6. Present status and future perspective of peptide-based vaccine therapy for urological cancer.
Obara W; Kanehira M; Katagiri T; Kato R; Kato Y; Takata R
Cancer Sci; 2018 Mar; 109(3):550-559. PubMed ID: 29345737
[TBL] [Abstract][Full Text] [Related]
7. Autoantibodies against P53 protein in patients with transitional cell carcinoma of the bladder.
Sanchez-Carbayo M; Chulia MT; Niveiro M; Aranda I; Mira A; Soria F
Anticancer Res; 1999; 19(4C):3531-7. PubMed ID: 10629648
[TBL] [Abstract][Full Text] [Related]
8. The correlation of p53 protein overexpression and p53 antibodies in serum of patients with transitional cell carcinoma of the urinary bladder.
Wunderlich H; Hindermann W; Hüller M; Reichelt O; Werner W; Schubert J; Kosmehl H
Urol Int; 2000; 64(1):13-7. PubMed ID: 10782026
[TBL] [Abstract][Full Text] [Related]
9. Serum anti-p53 antibodies in patients with lung cancer.
Mack U; Ukena D; Montenarh M; Sybrecht GW
Oncol Rep; 2000; 7(3):669-74. PubMed ID: 10767388
[TBL] [Abstract][Full Text] [Related]
10. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.
Lenner P; Wiklund F; Emdin SO; Arnerlöv C; Eklund C; Hallmans G; Zentgraf H; Dillner J
Br J Cancer; 1999 Feb; 79(5-6):927-32. PubMed ID: 10070892
[TBL] [Abstract][Full Text] [Related]
11. p53 autoantibodies in patients with urological tumours.
Lang C; Unteregger G; Kartarius S; Günther J; Bonkhoff H; Montenarh M; Zwergel T
Br J Urol; 1998 Nov; 82(5):721-6. PubMed ID: 9839589
[TBL] [Abstract][Full Text] [Related]
12. Tumour suppressor genes in urinary tract oncology.
Brewster SF; Gingell JC; Brown KW
Br J Urol; 1992 Dec; 70(6):585-90. PubMed ID: 1336697
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
